Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $367.9KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Durso Jerome Benedict | President and CEO | Aug 13 '26 | Buy | $2.95 | 15,000 | $44,250 | 62,500 | Aug 13 04:05 PM |
| Gill John | Director | Apr 06 '26 | Buy | $3.41 | 9,200 | $31,350 | 21,700 | Apr 06 04:05 PM |
| Weaver Gregory L | Chief Financial Officer | Apr 01 '26 | Buy | $3.15 | 10,000 | $31,499 | 38,078 | Apr 01 04:05 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.